Comparison of Heart Rate Blood Pressure Product Versus Age Predicted Maximum Heart Rate as Predictors of Cardiovascular Events During Exercise Stress Echocardiography

Mark Whitman BExSc , Carly Jenkins PhD ,
Surendran Sabapathy PhD , Lewis Adams PhD

PII: S0002-9149(19)30594-6
DOI: <https://doi.org/10.1016/j.amjcard.2019.05.027>
Reference: AJC 23968

To appear in: *The American Journal of Cardiology*

Received date: 3 March 2019
Revised date: 24 April 2019

Please cite this article as: Mark Whitman BExSc , Carly Jenkins PhD , Surendran Sabapathy PhD , Lewis Adams PhD , Comparison of Heart Rate Blood Pressure Product Versus Age Predicted Maximum Heart Rate as Predictors of Cardiovascular Events During Exercise Stress Echocardiography, *The American Journal of Cardiology* (2019), doi: <https://doi.org/10.1016/j.amjcard.2019.05.027>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Comparison of Heart Rate Blood Pressure Product Versus Age Predicted Maximum Heart
Rate as Predictors of Cardiovascular Events During Exercise Stress Echocardiography

Authors:

Mark Whitman, BExSca,b,c,*, Carly Jenkins, PhDa, Surendran Sabapathy, PhDb,d, Lewis
Adams, PhDb,d.

aCardiac Investigations Unit, Logan Hospital, Meadowbrook, Australia;

bMenzies Health Institute, Queensland, Australia;

cSchool of Human Movement and Nutrition Sciences, University of Queensland, Brisbane,
Australia;

dAllied Health Sciences, Griffith University, Gold Coast, Australia.

*Corresponding author and request for reprints:

Tel: 617 3299 8876; fax: 617 3299 8117.

Mailing address: Cardiac Investigations Unit, Logan Hospital, PO Box 6031, Yatala.
Queensland. 4207.

E-mail address: mark.whitman@health.qld.gov.au

Abstract

Exercise stress echocardiograms (ESE) are a functional cardiovascular (CV) test typically used for the investigation of coronary artery disease (CAD). ESEs are often terminated at a pre-determined age-predicted maximum heart rate (APMHR) to facilitate timely acquisition of ultrasound images at peak exercise. While an APMHR of 85% is often used, this has not been validated as a suitable termination endpoint. Heart rate blood pressure product (HRBPP) as an established measure of myocardial work may provide a more reliable assessment of cardiac workload. The aim of this study was to assess maximal HRBPP (MHRBPP) and APMHR as markers of cardiac workload during ESE, using CV events at mean follow-up as the outcome variable. Following exclusions, 712 patients being investigated for ischemic heart disease, performed an ESE to volitional fatigue using the standard Bruce protocol. Patient demographics and test data were collected and patients followed for 4.4 ± 2.1 years. Cut-points for MHRBPP (25060) (AUC 0.77) and APMHR (93.8% and 97.9%) (AUC 0.71) ($p=0.12$ for difference) were established from receiver operating characteristic analysis. Those achieving an APMHR $>85\%$ but MHRBPP <25060 had significantly more CV events than achieving an MHRBPP >25060 regardless of APMHR ($p<0.05$). In conclusion, the current study demonstrates the superior prognostic power of MHRBPP over APMHR alone for the prediction of future CV events in patients performing an otherwise negative ESE for the detection of myocardial ischemia.

Key Words: Rate Pressure Product, Exercise Stress Echocardiogram, Myocardial Ischemia, Double Product.

Generally, the diagnostic accuracy of the exercise stress echocardiogram (ESE) is superior to the exercise stress test (EST) however this often depends on the patient population being studied, the image quality and test interpreter skill level (1- 5). The added advantage of ESE is the acquisition of ultrasound images to detect regional wall motion abnormalities (RWMA) linked to myocardial ischemia, particularly when the resting electrocardiogram (ECG) is uninterpretable (5). ESEs are often terminated at an age-predicted maximum heart rate (APMHR) of 85% to allow the patient to move quickly into a supine position for peak image acquisition as RWMA may resolve quickly (1, 6, 7). Heart rate blood pressure product (HRBPP), as an established estimate of myocardial oxygen consumption and, therefore, myocardial work (8, 9), is often recorded during an ESE but not commonly used as a marker of sufficient cardiac workload (1). Maximum HRBPP (MHRBPP) has been shown to be a predictor of cardiovascular (CV) outcome during ESTs, displaying superiority over APMHR to predict CV events (10). Therefore, MHRBPP may provide a more reliable assessment of cardiac workload than APMHR for the prediction of CV events during ESEs. The aim of this study was to compare MHRBPP and APMHR as predictors of future CV events in intermediate risk patients performing an otherwise negative ESE.

Methods

The study sample was retrieved from the Logan Hospital, a public hospital in southeast Queensland, Australia, and was approved by the Metro South Health Service District Human Research Ethics Committee, conforming to the declaration of Helsinki. Retrospective data from consecutive ESEs performed between 01/01/2010 and 31/12/2014 for the investigation of inducible myocardial ischemia were included (n=783). Any test considered positive by RWMA, ECG criteria, symptoms, or patients with > mild resting left ventricular (LV) dysfunction (n=71) were excluded, as downstream management strategies would differ in this group. The total number of tests remaining for analysis was 712.

Echocardiography images were obtained with a Philips IE33 ultrasound machine (Philips Medical Systems, Andover, MA) in the left lateral decubitus position. Image analysis was performed as per American Society of Echocardiography guidelines (7). The treadmill exercise was administered on a computer-controlled treadmill system (Marquette Case, Milwaukee, WI), performed to volitional fatigue, using the standard Bruce protocol (11). Manual blood pressure measurements were taken by an experienced operator at least once every stage, at peak exercise, and a minimum of twice during recovery. HRBPP was calculated by multiplying heart rate by systolic blood pressure (SBP) throughout the test and MHRBPP was identified. Mean follow up was 4.4 ± 2.1 years by reference to medical records, inclusive of mortality registry or contact with the patients' general practitioners.

Quantitative data were summarised as mean $\pm$ standard deviation and the student t-test or Fisher's exact test were used where appropriate. To establish a cut-point for MHRBPP and APMHR, receiver operating characteristic (ROC) analysis was used to calculate sensitivity and specificity with respect to CV events (CV mortality, non-fatal myocardial infarction, stroke or heart failure (minimum stage C) (12), percutaneous coronary intervention (PCI) / balloon angioplasty or coronary artery bypass grafting) at mean follow-up as the outcome measure. The longest vertical deviation from the diagonal line was chosen as the optimal cut-point. Kaplan-Meier survival analysis was used to evaluate CV events, CV mortality and all-cause mortality for those above and below the optimal cut points. The log-rank test was used to assess statistical significance. Cox proportional hazard models were created to assess variables significant for CV events. Variables were selected from baseline differences between those with and without CV events (Table 1 and 2). Likewise, inability to achieve the ROC cut-points were included in the model with entry and multivariate retention set at 0.05 significance. Multivariate analysis was performed to assess factors influencing the ability to achieve the ROC cut-points including age, smoking status, heart rate and blood pressure

medications. Categorical data were compared using the chi-square or Fisher's exact test, where appropriate. Data analysis was performed using XLSTAT 2018.7 (Addinsoft, New York) with a 2-tailed p-value <0.05 considered statistically significant.

Results

Table 1 displays the physical attributes of the patients together with their ESE measures for those with and without CV events during follow-up. Table 2 lists the CV disease risk factors and medications of the patients at time of testing. Those with CV events were older, performed less exercise with less myocardial work during their test and had more resting abnormalities on their echocardiograms (Table 1). They also exhibited more CAD, used more medications and overall displayed a greater CV disease risk (Table 2).

ROC analyses revealed an optimal cut-point of 25060 for MHRBPP (sensitivity 76%, specificity 78.2%, [area under curve (AUC) 0.77]. For APMHR, the optimal cut-point was equal between 2 points; 93.8% (sensitivity 63.8%, specificity 69.4%) and 97.9% (sensitivity 79.3%, specificity 53.9%) (AUC 0.71). At 85% APMHR, the sensitivity and specificity were 27.6% and 91.8% respectively. The difference between the two models failed to reach statistical significance ($p = 0.12$) (Figure 1).

There was no CV mortality throughout the follow-up period. Figure 2 illustrates the Kaplan-Meier curves for all-cause mortality and CV events with respect to the MHRBPP cut point of 25060 and APMHR of 85%. There was no significant difference in all-cause mortality for all interactions of $\text{MHRBPP} > \text{or} \leq 25060$ and $\text{APMHR} > \text{or} \leq 85\%$ (Figure 2a). In contrast, the cumulation of CV events was significantly less in those achieving >25060 MHRBPP or $>85\%$ APMHR compared to $\text{MHRBPP} \leq 25060$ and $\text{APMHR} \leq 85\%$ ($p < 0.05$) (Figure 2b). From 3 years follow-up, those attaining a $\text{MHRBPP} > 25060$ had significantly less events than those reaching $>85\%$ APMHR ($p < 0.05$) (Figure 2b).

Table 3 shows the outcome of Cox proportional hazard analysis for predicting CV events. After adjustments, only age, the presence of diabetes, previous CAD and an MHRBPP <25000 remained as significant predictors.

No CV medication influenced the ability to achieve the cut-points for APMHR and MHRBPP. For all cut-point levels of APMHR (<85%, <94%, <98%) only a younger age was a significant factor for the inability to achieve above these levels ($p<0.05$). There was no significant factor influencing MHRBPP other than the components maximum heart rate and maximum SBP ($p<0.05$).

Discussion

The current study demonstrates MHRBPP as a reasonable prognostic measure of future CV events (AUC = 0.77). While the overall diagnostic model between MHRBPP and APMHR failed to reach significance ($p=0.12$) (Figure 1), no level of APMHR predicted future CV events (Table 3). In comparison, inability to achieve the ROC cut-point for MHRBPP >25060 was a strong uni and multivariate predictor of CV events (Table 3). An APMHR of 85% is often used as a marker of sufficient stress during treadmill exercise (13). Our study found this value exhibited poor sensitivity (27.6%) for the detection of future CV events in otherwise negative studies (Figure 1). The use of 85% APMHR comes from studies demonstrating that failure to achieve this level is a marker of chronotropic incompetence (14, 15). No study has shown this level of APMHR as a sufficient marker of cardiac workload during exercise yet many still use this as a termination point during exercise testing despite guideline recommendations (2, 16, 17). The current study shows even achieving an APMHR >85% did not predict a better outcome compared to an MHRBPP >25060 (Figure 2b).

There was a significant difference for CV event frequency during follow-up between those achieving an MHRBPP >25060 and those below (Figure 2b). Previous work by Whitman et al. demonstrated similar results in those with poor functional capacity but

MHRBPP >25000 during an EST (10). In the current study, resting LV dysfunction was found to be an independent predictor of future CV events (Table 3). Elhendy et al. demonstrated similar results with resting echocardiogram abnormalities and poorer CV outcomes in those unable to achieve 85% APMHR and, although not discussed, an inability to reach an HRBPP of 25000 during an ESE (15). Advancing age, diabetes, hypertension and the presence of CAD have all been shown to increase CV disease risk (18, 19). This is confirmed in the current study as these risk factors were all significantly different between the CV event group and the no CV event group ($p<0.05$) (Table 2). The greatest predictor for CV events in the current study was failure to reach an MHRBPP of >25060 (Table 3). In a study by Sadrzadeh Rafie et al. (20), HRBPP reserve (the difference between rest and maximal exercise) was a stronger predictor of CV outcome than even exercise capacity, a known CV prognostic marker (21). Similarly, we found the inability to achieve an MHRBPP >25060 to be a strong CV event predictor with exercise capacity failing to predict CV events in the current study (Table 3). The ability to increase SBP alone during an ESE has been associated with a significantly lower risk of future CV events (22). Therefore, it appears the blood pressure response during exercise is equally as important as the heart rate response and should be used in conjunction (i.e. MHRBPP) to maximise the prognostic power for the prediction of CV events.

There are some limitations to this study. Firstly, our study is a single centre cohort and therefore the decision to perform an ESE may have been subject to selection bias. Secondly, while most of our patients were risk stratified as intermediate/moderate risk for CV disease, the total event rate during follow-up was only 8% suggesting a lower overall risk. Finally, like all predictive models, care should be taken not to replace clinical suspicion in patients deemed to be at sufficient future CV event risk.

In conclusion, the current study demonstrates the superior prognostic power of MHRBPP over APMHR alone for the prediction of future CV events in patients performing an otherwise negative ESE to volitional fatigue. While APMHR has been used as a marker of sufficient myocardial work in the past, the current study demonstrates the value of MHRBPP during exercise testing and warrants further investigation in this area.

Acknowledgements

Mark Whitman is supported by an Australian Government Research Training Program Scholarship.

Disclosures

The authors have no conflicts of interest to disclose.

1. Marwick T. Stress Echocardiography. *Heart* 2003;89:113-118.
2. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD Jr, Winters WL, Yanowitz FG, Ritchie JL, Gibbons RJ, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA Guidelines for Exercise Testing – A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). *J Am Coll Cardiol* 1997;30:260-315.
3. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. *JAMA* 1998;280:913-920.
4. Roger VL, Pellikka PA, Oh JK, Bailey KR, Tajik AJ. Identification of multivessel coronary artery disease by exercise echocardiography. *J Am Coll Cardiol* 1994;24:109-114.
5. Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Rosenbaum L, Shaw LJ, Stainback RF, Allen JM; American College of Cardiology Foundation Appropriate Use Criteria Task Force. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2014;63:380-406.

6. Becher H, Chambers J, Fox K, Jones R, Leech GJ, Masani N, Monaghan M, More R, Nihoyannopoulos P, Rimington H, Senior R, Warton G; British Society of Echocardiography Policy Committee. BSE procedure guidelines for the clinical application of stress echocardiography, recommendations for performance and interpretation of stress echocardiography: a report of the British Society of Echocardiography Policy Committee. *Heart* 2004;90:23-30.
7. Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG; American Society of Echocardiography. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. *J Am Soc Echocardiogr* 2007;20:1021–1041.
8. Gobel FL, Norstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. *Circulation* 1978;57:549-556.
9. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. *Circulation* 1974;50:1179-1189.
10. Whitman M, Sabapathy S, Jenkins C, Adams L. Is Downstream Cardiac Testing Required in patients with Reduced Functional Capacity and otherwise Negative Exercise Stress Test? A Single Centre Observational Study. *Cardiol J* 2018;Sept 20. doi: 10.5603/CJ.a2018.0099. [Epub ahead of print].
11. Bruce RA, Blackmon JR, Jones JW, Strait G. Exercising testing in adult normal subjects and cardiac patients. *Pediatrics* 1963;32:suppl 742-756.

12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:1810-1852.
13. Shaw L, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, Krawczynska E, Cerqueira M, Maddahi J; Myoview Multicenter Registry. Prognostic Value of Normal Exercise and Adenosine 99mTc-Tetrofosmin SPECT Imaging: Results from the Multicenter Registry of 4,728 Patients. *J Nucl Med* 2003;44:134-139.
14. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart study. *Circulation* 1996;93:1520-1526.
15. Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pelikka PA. Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. *J Am Coll Cardiol* 2003;42:823-830.
16. Jain M, Nkonde C, Lin BA, Walker A, Wackers FJ. 85% of maximal age-predicted heart rate is not a valid endpoint for exercise treadmill testing. *J Nucl Cardiol* 2011;18:1026-1035.
17. Pinkstaff S, Peberdy MA, Kontos MC, Finucane S, Arena R. Quantifying Exertion Level during Exercise Stress Testing Using Percentage of Age-Predicted Maximal Heart Rate, Rate Pressure Product, and Perceived Exertion. *Mayo Clin Proc* 2010;85:1095-1100.

18. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease: six year follow-up experience: the Framingham study. *Ann Intern Med* 1961;55:30–50.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. *JAMA* 2003;289:2560–2572.
20. Sadrzadeh Rafie AH, Sungar GW, Dewey FE, Hadley D, Myers J, Froelicher VF. Prognostic value of double product reserve. *Eur J Cardiovasc Prev Rehabil* 2008;15:541–547.
21. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Thisted RA. The prognostic value of a nomogram for exercise capacity in women. *N Engl J Med* 2005;353:468–475.
22. Bouzas-Mosquera MC, Bouzas-Mosquera A, Peteiro J. Excessive blood pressure increase with exercise and risk of all-cause mortality and cardiac events. *Eur J Clin Invest* 2016;46:833–839.

Figure 1. Receiver operating characteristic curve for maximum heart rate blood pressure product (MHRBPP) and age-predicted maximal heart rate (APMHR). The bold arrow indicates the optimal cut-point for MHRBPP. The dotted arrow (93.8%) and dashed arrow (97.9%) indicate the optimal cut-points for APMHR. The black dot specifies the data point at 85% APMHR.

Figure 2. Kaplan Meier curve for a. all-cause mortality and b. cardiovascular events for maximum heart rate blood pressure product $>$ and $\leq$ 25060 and age-predicted maximum heart rate $>$ and $\leq$ 85%

<i>Variable</i>	<i>CV Events (n=58)</i>	<i>No CV Events (n=657)</i>	<i>p-Value</i>
<i>Age (years)</i>	60.0 ± 10.4 #	52.8 ± 11.5	<0.01
<i>Men</i>	36 (62.1%)	316 (48.1%)	0.25
<i>Resting heart rate (bpm)</i>	75 ± 14	79 ± 14 #	0.02
<i>Resting systolic blood pressure (mmHg)</i>	132 ± 19	128 ± 18	0.18
<i>Resting heart rate blood pressure product</i>	9820 ± 2311	10212 ± 2435	0.24
<i>Maximum heart rate (bpm)</i>	143 ± 18*	164 ± 19*#	<0.01
<i>Maximum systolic blood pressure (mmHg)</i>	166 ± 27*	171 ± 21*	0.08
<i>Maximum heart rate blood pressure product</i>	23762 ± 4839*	28045 ± 4731*#	<0.01
<i>Test Duration (min:sec)</i>	7:17 ± 2:48	8:42 ± 2:33 #	<0.01
<i>Metabolic equivalents</i>	8.8 ± 3.0	10.4 ± 2.8 #	<0.01
<i>Resting regional wall motion abnormalities</i>	9 (15.5%) #	25 (3.8%)	<0.01
<i>Diastolic dysfunction</i>	14 (24.1%)	89 (13.6%)	0.09
<i>Mildly impaired resting ejection fraction</i>	4 (6.9%) #	10 (1.5%)	0.02

Table 1. Physical characteristics and ESE measures for those with and without cardiovascular (CV) events during follow-up. Values show number of cases (n), mean ± SD or percentage (%) of the group. * significant from resting values p<0.05.

significant between CV event and no CV event group p<0.05.

<i>Variable</i>	CV Events (n=58)	No CV Events (n=657)	p-Value
<i>CV disease risk factors</i>	3.1 ± 1.3	2.1 ± 1.3	<0.01
<i>No risk factors for CV disease</i>	3 (5.2%)	78 (11.9%)	0.19
<i>Family history of CV disease</i>	17 (29.3%)	204 (31.1%)	>0.99
<i>Diabetes Mellitus</i>	19 (32.8%)	112 (17.0%)	0.03
<i>Smoker</i>	14 (24.1%)	156 (23.7%)	>0.99
<i>Hypertension</i>	39 (67.2%)	282 (42.9%)	0.04
<i>Dyslipidemia</i>	45 (77.6%)	322 (49.0%)	0.04
<i>Obesity</i>	17 (29.3%)	220 (33.5%)	0.78
<i>Prior coronary artery disease</i>	31 (53.4%)	91 (13.9%)	<0.01
<i>Medications per patient</i>	3.3 ± 1.9	1.7 ± 1.7	<0.01
<i>No medications</i>	6 (10.3%)	232 (35.3%)	<0.01
<i>β blockers</i>	31 (53.4%)	148 (22.5%)	<0.01
<i>Ca²⁺ blockers</i>	13 (22.4%)	71 (10.8%)	0.04
<i>Angiotensin converting enzyme inhibitors</i>	22 (37.9%)	139 (21.1%)	0.03
<i>Angiotensin receptor blockers</i>	13 (22.4%)	115 (17.5%)	0.49
<i>Nitrates</i>	9 (15.5%)	15 (2.3%)	<0.01
<i>Statins</i>	35 (60.3%)	269 (40.9%)	0.10
<i>Diuretics</i>	7 (12.1%)	44 (6.7%)	0.19
<i>Aspirin</i>	36 (62.1%)	244 (37.1%)	0.03
<i>Non-vitamin K antagonist</i>	2 (3.4%)	3 (0.5%)	0.06
<i>P2y₁₂ inhibitor</i>	16 (27.6%)	53 (8.1%)	<0.01
<i>Warfarin</i>	4 (6.9%)	10 (1.5%)	0.02

Table 2. Cardiovascular (CV) disease risk factors and medications at time of stress test for those with and without CV events during follow-up . Values show number of cases (n), ± SD or percentage (%) of the group.

Variable	Univariate Hazard Ratio (95% CI)	Chi Square	p-Value	Multivariate Hazard Ratio (95% CI)	Chi Square	p-Value
<i>Age</i>	1.06 (1.02-1.10)	9.1	0.003	1.06 (1.03-1.09)	16.8	<0.0001
<i>Men</i>	1.14 (0.54-2.40)	0.2	0.738	-	-	-
<i>Diabetes Mellitus</i>	2.57 (1.28-5.17)	7.0	0.008	2.77 (1.48-5.17)	10.2	0.001
<i>Hypertension</i>	2.58 (1.09-6.11)	4.7	0.031	2.02 (0.91-4.48)	2.9	0.086
<i>Dyslipidemia</i>	0.94 (0.44-2.00)	0.1	0.872	-	-	-
<i>Prior coronary artery disease</i>	3.20 (1.51-6.80)	9.2	0.002	2.56 (1.43-4.57)	10.0	0.002
<i>β-Blocker use</i>	1.22 (0.63-2.37)	0.4	0.551	-	-	-
<i>Calcium channel blocker use</i>	0.63 (0.28-1.42)	1.2	0.265	-	-	-
<i>Angiotensin converting enzyme inhibitor use</i>	1.36 (0.70-2.66)	0.8	0.365	-	-	-
<i>Nitrate use</i>	2.72 (1.05-7.05)	4.2	0.040	2.17 (0.99-4.75)	3.7	0.052
<i>Aspirin use</i>	0.66 (0.34-1.27)	1.6	0.213	-	-	-
<i>P2Y12 inhibitor use</i>	0.51 (0.23-1.13)	2.7	0.099	-	-	-
<i>Warfarin</i>	0.33 (0.08-1.41)	2.3	0.133	-	-	-
<i><7:17min:sec treadmill time</i>	3.64 (0.45-29.8)	1.5	0.228	-	-	-
<i><8.8 metabolic equivalents</i>	0.19 (0.02-1.56)	2.4	0.122	-	-	-
<i><85% Age predicted maximum heart rate</i>	1.53 (0.67-3.48)	1.1	0.311	-	-	-
<i><94% Age predicted maximum heart rate</i>	0.63 (0.25-1.55)	1.1	0.312	-	-	-
<i><98% Age predicted maximum heart rate</i>	1.83 (0.68-4.92)	1.4	0.232	-	-	-
<i>Resting regional wall motion abnormalities</i>	0.30 (0.00-0.91)	4.6	0.033	0.43 (0.15-1.20)	2.6	0.105
<i>Maximum heart rate blood pressure product <25060</i>	7.64 (3.40-17.2)	24.2	<0.0001	6.21 (3.26-11.8)	30.9	<0.0001
<i>Mildly impaired resting left ventricular ejection fraction</i>	6.03 (1.30-27.9)	5.3	0.022	3.59 (0.94-13.8)	3.5	0.063

Table 3. Univariate and multivariate predictors of cardiovascular events from exercise stress echocardiogram results.